Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human SNCA protein

Cat.No. : SNCA-237H
Product Overview : Recombinant Human SNCA(amino acids 96-140) was expressed in E. coli.
  • Specification
  • Gene Information
  • Related Products
Description : Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.
Source : E. coli
Species : Human
Predicted N Terminal : Met
Form : Supplied as a liquid In 20mM Tris-HCl buffer, pH 7.5, containing 0.1 M NaCl.
Molecular Mass : 5.2 kDa (46 aa), confirmed by MALDI-TOF.
Protein length : amino acids 96-140
AA Sequence : MKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
Purity : > 95% by SDS - PAGE
Applications : SDS-PAGE
Notes : Small volumes of alpha Synuclein 96140 recombinant protein may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice.
Storage : Store at 4 centigrade for short term storage (1/2 weeks). Aliquot and store at -20 centigrade or - 70 centigrade for long term storage. Avoid repeated freeze/thaw cycles.
Concentration : 1 mg/ml (lot specific)
Gene Name : SNCA synuclein, alpha (non A4 component of amyloid precursor) [ Homo sapiens ]
Official Symbol : SNCA
Synonyms : SNCA; synuclein, alpha (non A4 component of amyloid precursor); PARK1, PARK4, Parkinson disease (autosomal dominant, Lewy body) 4; alpha-synuclein; alpha synuclein; NACP; PD1; synuclein alpha-140; non A-beta component of AD amyloid; PARK1; PARK4; MGC110988;
Gene ID : 6622
mRNA Refseq : NM_000345
Protein Refseq : NP_000336
MIM : 163890
UniProt ID : P37840
Chromosome Location : 4q21.3-q22
Pathway : Alpha-synuclein signaling, organism-specific biosystem; Alzheimers disease, organism-specific biosystem; Alzheimers disease, conserved biosystem; Amyloids, organism-specific biosystem; Disease, organism-specific biosystem; EGFR1 Signaling Pathway, organism-specific biosystem; Parkinsons disease, organism-specific biosystem;
Function : Hsp70 protein binding; alpha-tubulin binding; arachidonic acid binding; calcium ion binding; copper ion binding; cysteine-type endopeptidase inhibitor activity involved in apoptotic process; dynein binding; NOT fatty acid binding; ferrous iron binding; histone binding; identical protein binding; kinesin binding; magnesium ion binding; oxidoreductase activity; NOT phospholipase D inhibitor activity; phosphoprotein binding; protein binding; tau protein binding; zinc ion binding;

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
Can SNCA protein levels in cerebrospinal fluid be used as a diagnostic marker for Parkinson's disease? 10/11/2022

Yes, elevated levels of SNCA protein in cerebrospinal fluid can be indicative of Parkinson's disease.

What potential therapeutic strategies target SNCA protein for Parkinson's disease treatment? 03/27/2022

Therapies may include reducing SNCA aggregation or preventing its misfolding.

Are there any genetic mutations related to SNCA protein that increase the risk of Parkinson's disease? 10/17/2018

Yes, certain mutations in the SNCA gene are associated with familial Parkinson's disease.

How is SNCA protein associated with neurodegenerative diseases? 06/11/2016

Aggregates of misfolded SNCA protein are implicated in various neurodegenerative diseases, including Parkinson's disease.

Are there any ongoing clinical trials investigating SNCA-related therapies? 05/27/2016

Yes, several clinical trials are exploring treatments targeting SNCA protein in Parkinson's disease.

Customer Reviews (3)

Write a review
Reviews
08/31/2020

    Its integrity and reliability make it an ideal choice to address the specific objectives of my research.

    03/12/2020

      Their profound knowledge and expertise will undoubtedly help me overcome any challenges that arise, and their prompt assistance ensures a seamless progression of my research.

      10/16/2017

        In addition to the exceptional quality of the protein, the manufacturer's support extends beyond the product itself.

        Ask a Question for All SNCA Products

        Required fields are marked with *

        My Review for All SNCA Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends